Cita APA

Lee, E. Q., Zhang, P., Wen, P. Y., Gerstner, E. R., Reardon, D. A., Aldape, K. D., . . . Mehta, M. P. (2020). NRG/RTOG 1122: Phase II double-blinded, placebo-controlled study of bevacizumab with/without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer.

Chicago Style Citation

Lee, Eudocia Q., et al. "NRG/RTOG 1122: Phase II Double-blinded, Placebo-controlled Study of Bevacizumab With/without Trebananib in Patients With Recurrent Glioblastoma or Gliosarcoma." Cancer 2020.

Cita MLA

Lee, Eudocia Q., et al. "NRG/RTOG 1122: Phase II Double-blinded, Placebo-controlled Study of Bevacizumab With/without Trebananib in Patients With Recurrent Glioblastoma or Gliosarcoma." Cancer 2020.